Belite Bio Announces Registered Direct Offering of $15 Million The offering was to a single large existing institutional shareholder

Belite Bio Announces

Registered Direct Offering of $15 Million

The offering was to a single large existing institutional shareholder

SAN DIEGO, CA, August 6, 2025 (GLOBE

NEWSWIRE) / -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company

focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced

that it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares ("ADSs")

and warrants to purchase 230,770 ADSs, at a purchase price of $65 per ADS and accompanying warrant, pursuant to a registered direct offering.

The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the

potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing

of the offering is expected to occur on or about August 8, 2025, subject to the satisfaction of customary closing conditions.

The offering was to a single large existing

institutional shareholder.

The Company intends to use the net proceeds

from the offering for working capital and general corporate purposes.

Titan Partners Group, a division of

American Capital Partners, is acting as the sole placement agent for the offering.

This offering is being made pursuant

to a shelf registration statement on Form F-3 (File No. 333-284521) previously filed with the U.S. Securities and Exchange Commission

(the "SEC") and declared effective on January 27, 2025. The offering is made only by means of a prospectus supplement, which

will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the prospectus

supplement may be obtained, when available, by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World

Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.

This press release shall not constitute

an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such

state or jurisdiction.

Belite Bio, Inc is a clinical stage

drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical

needs, such as Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic

Forward-Looking Statements

This press release contains forward-looking

statements, including statements about future expectations, plans and prospects, as well as any statements regarding matters that are

not historical facts, and any other statements containing the words "expect", "will", "believe",

"target", and other similar expressions. No assurance can be given that the offering will be completed on the terms described.

Completion of the offering and the terms thereof are subject to numerous factors, many of which are beyond the control of BLTE, including,

without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the

prospectus supplement and accompanying prospectus included in the registration statement. Actual results may also differ materially from

those indicated in the forward-looking statements as a result of various important factors related to BLTE's business, including

but not limited to BLTE's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug

candidates, which may not support further development or regulatory approval; expectations for the timing of initiation, enrollment and

completion of, and data relating to, its clinical trials; the content and timing of decisions made by the relevant regulatory authorities

regarding regulatory approval of BLTE's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully

discussed in the "Risk Factors" section in BLTE's filings with the U.S. Securities and Exchange Commission. All forward-looking

statements are based on information currently available to BLTE, and BLTE undertakes no obligation to publicly update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Media and Investor Relations Contact:

Jennifer Wu / ir@belitebio.com

Julie Fallon / belite@argotpartners.com